Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics Delivers 14 Human Genomes; Pfizer Among Customers


The headline of this article has been changed to clarify that not all customers have received data yet.

By Julia Karow

Complete Genomics said this week that it has sequenced, analyzed, and delivered 14 human genomes to early-access customers since March. It has also sequenced a single genome for Harvard's Personal Genome Project.

The company said it currently has more than a dozen customers, including Pfizer, the Flanders Institute for Biotechnology, Duke University, Brigham & Women's Hospital, the HudsonAlpha Institute for Biotechnology, and the Ontario Institute for Cancer Research, in addition to the Institute for Systems Biology and the Broad Institute, which Complete announced previously.

Complete Genomics is conducting pilot projects for these customers, each comprised of five to 10 genomes, giving them an opportunity to evaluate the company's human genome sequencing service.

The pilot projects include disease studies in the areas of melanoma; breast, lung, and colorectal cancer; HIV; and schizophrenia. Complete Genomics said previously that its charges approximately $20,000 per genome for the pilot projects. The firm is targeting a price of $5,000 per genome for the commercial launch of the service, which is slated for January 2010.

Complete Genomics also sequenced a single human genome for the Personal Genome Project, a research study led by Harvard Medical School. George Church, principal investigator of the PGP and a member of Complete Genomics' scientific advisory board, said in a statement issued by the firm that his team has cross-validated the data set it obtained for the genome, including a list of variants, to gauge the technology's accuracy.

"I am pleased with the quality of the data provided," he said. "Complete Genomics’ technology can clearly deliver high quality genomic data, which compare favorably with other published results, and at a low cost. I look forward to continuing to work with the company as it scales up the process to sequence thousands of genomes next year.”

Complete Genomics plans to launch its human genome sequencing service commercially in January 2010 and to sequence 10,000 genomes next year. Last month, it raised $45 million in private equity from a Series D funding (see In Sequence 8/25/2009).

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.